Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Natera, Inc.
- 入组人数
- 400
- 试验地点
- 1
- 主要终点
- Number of Completed Participants with Blood, Urine and Residual Tissue Specimens Collected
研究概览
简要总结
The SCORE-NMIBC study is a prospective, multi-center, study designed to collect data and biological samples from participants diagnosed with non-muscle Invasive Bladder Cancer (NMIBC). Study participants will undergo research blood and urine collections, as well as tumor tissue collected as part of a standard-of-care procedure(s), for use in research. Collected samples and data will be analyzed to evaluate biomarkers associated with development and validation of cancer monitoring and detection assays ("Natera cancer monitoring and detection test(s)").
详细描述
The study is designed to evaluate the clinical performance of Natera's molecular residual disease (MRD) assays in detecting ctDNA in patients diagnosed with NMIBC. The goal is to assess the ability of the assay to identify minimal residual disease, monitor disease recurrence, and evaluate treatment response on therapy. No individual test results from the study testing will be provided to participants or their treating clinicians.
Participants who meet the study eligibility criteria will be invited to enroll in the study. Informed consent form (ICF) (paper or electronic) will be signed by the participant prior to study procedures. Participants will provide study-specific blood and urine samples at protocol defined timepoints.
The SCORE-NMIBC study includes two participant cohorts:
Cohort A - Intravesical Therapy and/or Systemic Therapy Cohort B - Cystectomy
Participants may be followed for up to three years, including up to two years of blood and urine collection and up to one year of data-only follow-up.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is at least 18 years of age or older.
- •Eastern Cooperative Oncology Group performance status ≤
- •Patient has a suspected high risk non-muscle invasive bladder cancer.
- •Note: The AUA/SUO risk stratification for primary non-muscle invasive bladder cancer will be used to determine high risk of tumor progression based on clinic and pathologic prognostic factors (Holzbeierlein et al., 2024):
- •High grade T
- •Any recurrent, High-grade TA.
- •High grade TA, >3 cm (or multifocal).
- •BCG failure in high grade patient.
- •Any variant histology.*
- •*e.g. Micropapillary, plasmacytoid, small cell/neuroendocrine, and sarcomatoid histologies (in pure or mixed form with associated urothelial carcinoma)
- •Any lymphovascular invasion.
- •Any high grade prostatic urethral invasion.
- •Meet the following criteria:
- •a. Cohort A: i. Participant has high risk ≤ T1 bladder cancer and is eligible for intravesical therapy or cystectomy. ii. Participant has been treated with intravesical and/or systemic therapy for high risk ≤ T1 bladder cancer and is entering surveillance. b. Cohort B i. Participant has high risk ≤ T1 bladder cancer and undergoing primary treatment with cystectomy. ii. Patients undergoing cystectomy following recurrence or progression of high risk ≤ T1 bladder cancer and where ≤ T1 bladder cancer is confirmed on cystectomy surgical pathology.
- •Willing and able to tolerate blood draws according to Natera standard process.
- •Willing to provide urine collection samples.
- •Able to consent to and provide residual tumor tissue for research.
- •Willing and able to comply with the study requirements.
排除标准
- •Pregnant or breastfeeding.
- •Prior history and treatment for any cancer (including muscle invasive bladder cancer) within the past year, or if they have any other active cancer, with the exception of participants who have undergone surgical removal of basal or squamous skin cancers, as well as those who have received NMIBC-directed therapy, including those undergoing cystectomy for primary NMIBC or after recurrence/progression of NMIBC.
- •Diagnosis of >T1 bladder cancer at time of enrollment.
- •Tumor tissue unavailable and/or consists only of carcinoma in situ (CIS) disease.
- •At time of enrollment, has undergone or plans to undergo any ctDNA or utDNA testing to assess MRD, with the exception of one-time comprehensive genomic profiling for therapeutic drug selection.
- •History of bone marrow or organ transplant.
- •Serious medical conditions that may adversely affect ability to participate in the study.
研究组 & 干预措施
Cohort A - Intravesical Therapy
Samples collected at enrollment, before repeat TURBT (if done), then every 6 weeks during induction, then every 3 months for 2 years.
Cohort A - Systemic Therapy
Samples collected at enrollment, before repeat TURBT (if done), at treatment start, at first follow-up, then every 3 months for 2 years.
Cohort B - Cystectomy
Samples collected at enrollment, before repeat TURBT (if done), pre- and post-cystectomy (blood only post-op), then every 3 months for 2 years if NMIBC is confirmed on pathology.
结局指标
主要结局
Number of Completed Participants with Blood, Urine and Residual Tissue Specimens Collected
时间窗: 3 Years
The primary outcome will be measured as the number of participants who complete collection of clinically characterized, de-identified whole blood, urine and residual tissue specimens. The planned number of completed participants is 225. The specimens and data will be used in development and validation of cancer monitoring and detection assays.
次要结局
- Number of Completed Participants with Blood, Urine and Residual Tissue Specimens Evaluated for Biomarkers(3 Years)